Abstract
Residents of informal urban settlements have a high risk of COVID-19 exposure and have less access to medical care, making vaccine-driven prevention critical in this vulnerable population. Despite robust vaccination campaigns in Brazil, vaccine uptake and timing continue to be influenced by social factors and contribute to health disparities. To address this, we conducted a sequential survey in a cohort of 717 adults in an urban favela in Salvador, Brazil where participants were interviewed in 2020, before vaccines were rolled out, and in 2022, after primary and booster dose distribution. We collected data on demographics, social characteristics, and COVID-19 vaccination status and intent. Primary series uptake was high (91.10% for 1st dose and 94.74% for 2nd dose among eligible); however, booster uptake was lower (63.51% of eligible population) at the time of the second interview, suggesting a decreasing interest in vaccination. To account for both vaccine refusal and delays, we conducted a Cox time-to-event analysis of dose uptake using sequential independent outcomes. Exposure times were determined by dose eligibility date to account for age and comorbidities. Intent to vaccinate in 2020 (hazard ratio [HR]: 1.54, CI: [1.05, 1.98]) and age (HR: 1.27, CI: [1.01, 2.08]) were associated with higher vaccination rates for the 1st dose. Males were less likely to receive the 1st dose (HR: 0.61, CI: [0.35, 0.83]), and, compared to catholics, 2nd dose uptake was lower for those identifying with Pentecostalism (HR: 0.49, CI: [0.37, 0.66]) and without a religion (HR: 0.49, CI: [0.37, 0.66]), with the latter association disappearing after controlling by age. Risk perception was associated with 2nd dose uptake (HR: 1.15, CI: [1.08, 1.26]). The role of sex and religion in vaccination behavior highlights the need for targeted outreach and interfacing with local organizations. The data offers lessons to build a long-term COVID-19 vaccination strategy beyond availability.
Competing Interest Statement
A.I.K serves as an expert panel member for Reckitt Global Hygiene Institute, and a consultant for Regeneron Pharmaceuticals, and has received grants from Merck and Regeneron Pharmaceuticals for research related to COVID-19, all of which are outside the scope of the submitted work. M.O.F has past stock ownership in GlaxoSmithKline. Other authors declare no conflict of interest.
Funding Statement
Funding: This work was supported by grants from the National Institutes of Health (https://www.nih.gov; R01 AI052473, U01AI088752, R01 TW009504 and R25 TW009338 to A.I.K), the UK Medical Research Council (https://mrc.ukri.org; MR/T029781/1 to F.C.), the Wellcome Trust (https://wellcome.org; 102330/Z/13/Z; 218987/Z/ 19/Z to F.C.), the Bill and Melinda Gates Foundation (https://www.gatesfoundation.org; OPP1211988 to M.G.R. and F.C.), the Burroughs-Wellcome Fund (https://www.bwfund.org; ASTMH Postdoctoral Fellowship to M.O.F.), the William H. Prusoff Foundation (Postdoctoral Fellowship to M.O.F.), Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior Brasil [Coordination for the Improvement of Higher Education Personnel] (Doctoral scholarship to J.P.A.T., Finance Code 001), the Sendas Family Fund at the Yale School of Public Health (to A.I.K.), and the Yale College Public Service Grant (to M.D.). This funding source had no role in the design of this study and will not have any role during its execution, analyses, interpretation of the data, decision to publish, or preparation of the manuscript
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board o the Instituto Goncalo Moniz, Oswaldo Cruz Foundation (Fiocruz), the Brazilian National Commission for Ethics in Research (CAAE 35405320.0.1001.5030), and the Yale University Human Research Protection Program (2000031554) all gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Correcting typo in article information
Data Availability
Limited data to reproduce key results is available upon reasonable requests to the authors.
